Tetralogic Closes $23M Second Tranche in Series C
By Catherine Shaffer
Thursday, January 6, 2011
Tetralogic Pharmaceuticals Corp., of Malvern, Pa., is wasting no time putting its series C financing to work. The company closed a second and final tranche of $23 million, out of a total $37 million, and has already dosed its first cohort in a Phase Ib/IIa open-label, non-randomized, dose-escalation safety and tolerability study of TL32711 for advanced or metastatic solid tumors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.